Pediatric Cancer Clinical Trials

7 trials identified.

ANBL1232 Study to Guide Therapy Non-High-Risk Neuroblastoma
Principal Investigator: Wagner, Lars
Protocol Number: PRO00059254

Age Group: Children
Scope: National

Phase: III (Cancer Control)
Disease Site: Brain and Nervous System

Contact: Duke Recruitment Innovation Center
Phone: 919.681.5698

What is the Condition Being Studied?
Non-High Risk Neuroblastoma
What is the Purpose of this Study?
We are doing this study to figure out which children need treatment and what the best treatment is for newly diagnosed neuroblastoma.
Who Can Participate in the Study?
Children with newly diagnosed neuroblastoma who

Group A: Are less than 12 months old with newly diagnosed Stage L1 neuroblastoma.

Group B: Children who are less than 18 months old with newly diagnosed Stage L2 neuroblastoma.

Group C: Children who are less than 18 months old with newly diagnosed Stage Ms neuroblastoma.

No prior radiotherapy or chemotherapy, except dexamethasone, is allowed.
Children must not have had surgery to remove the primary tumor.
What is Involved?
If you choose to have your child this study, he or she will be put into a group based on certain features of their disease.

Group A is for children younger than one year old with newly diagnosed Stage L1 neuroblastoma
Subjects will be closely observed and will not have a biopsy or surgery on this trial.

Group B is for children younger than 18 months old with newly diagnosed Stage L2 neuroblastoma
Instead of starting treatment at diagnosis, these children will be closely monitored for tumor growth or spread. They may go on to have chemotherapy and/or have surgery if the tumor grows.

Group C is for children younger than 18 months with newly diagnosed Stage Ms neuroblastoma
Children who are very young and those with symptoms or unfavorable tumor features will start chemotherapy sooner than usual.

We will use a symptom scoring system to decide when to stop chemotherapy for all children who go on to have chemotherapy.


Participating Institutions:
  • Duke University Health System
View this trial at ClinicalTrials.gov

AHOD1331 Randomized Phase III Study for Newly Diagnosed Classical Hodgkin Lymphoma
Principal Investigator: Wagner, Lars
Protocol Number: PRO00065203

Age Group: Both
Scope: National

Phase: III (Cancer Control)
Disease Site: Hodgkin Lymphoma

Contact: Duke Recruitment Innovation Center
Phone: 919.681.5698

What is the Condition Being Studied?
Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
What is the Purpose of this Study?
We are doing this study to compare the effects (good and/or bad) of standard treatment and when brentuximab vedotin is added to standard treatment in newly diagnosed high-risk Hodgkin lymphoma patients to find out which one is better.
Who Can Participate in the Study?
Children or young adults who:
- Are age 2-22 
- Are newly diagnosed Classical Hodgkin Lymphoma
- Have no previous chemo or radiation therapy
What is Involved?
If you choose to be in the study, you will:

- Be randomized (like the flip of a coin) to get either:

 1. Standard Treatment: Get 5 cycles (21 days each) of Doxorubicin (A), bleomycin (B), vincristine (V), etoposide (E), prednisone (P) and cyclophosphamide (C)

 2. Experimental Treatment: Get 5 cycles (21 days each) of treatment with the following drugs: Brentuximab vedotin (Bv), doxorubicin (A), vincristine (V), etoposide (E), prednisone (P) and cyclophosphamide (C). 

- Get an evaluation by PET or CT scans to see how the disease is responding to treatment.
- Get Response Adapted Targeted Radiation if needed.
- Have your parent fill out questionnaires regarding financial costs at each time point 
Participating Institutions:
  • Duke University Health System
View this trial at ClinicalTrials.gov

AGCT1531 for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Principal Investigator: Wagner, Lars
Protocol Number: PRO00084265

Age Group: Both
Scope: National

Phase: III (Cancer Control)
Disease Site: Ovary

Contact: Duke Recruitment Innovation Center
Phone: 919.681.5698

What is the Condition Being Studied?
Pediatric and Adult Patients with Germ Cell Tumors
What is the Purpose of this Study?
We are doing this study to see if we keep an eye on patients with low risk germ cell tumors after your tumor is removed, will it work like following surgery with chemotherapy and/or more surgery.

For the standard risk groups 1 and 2, we want to compare the effects of carboplatin with cisplatin for patients with standard risk germ cell tumors to find out which one is better. 


Who Can Participate in the Study?
Female children and adults who:
-Are aged 49 or younger
-Have primary extracranial germ cell tumor
-Have received prior systemic therapy 
What is Involved?
If you choose to join this study, you will:

-Be assigned to one of the following groups: 
-- Low risk, standard risk 1 or standard risk 2

If you are in:
- Low risk group:
-- Be closely watched for 2 years and less frequently for years 3-5
-- Get blood tests and imaging tests to see if your tumor has came back

- Standard risk 1 and 2 groups: 
-- Be put into one of two groups (Like the flip of a coin) to get chemotherapy with bleomycin, etoposide and either cisplatin (standard) or carboplatin (experimental). 
-- Get one of the two treatments for either 3 or 4 cycles that last 3 weeks (21 days) each.
-- Have tissue and scans from your tumor tested
Participating Institutions:
  • Duke University Health System
View this trial at ClinicalTrials.gov

ADVL1622 Phase 2 Trial of XL184 (Cabozantinib)
Principal Investigator: Wagner, Lars
Protocol Number: PRO00084400

Age Group: Both
Scope: National

Phase: II (Cancer Control)
Disease Site: Soft Tissue

Contact: Duke Recruitment Innovation Center
Phone: 919.681.5698

What is the Condition Being Studied?
Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
What is the Purpose of this Study?
We are doing this study to find out what effects (good and/or bad) the study drug XL184 has on your tumor or type of cancer.

We also want to learn more about how XL184 works against cancer cells and other immune cells. 
Who Can Participate in the Study?
Children and adults who:
-Are age 2-30 years old
-Have recurrent or refractory disease, or newly diagnosed disease with rare tumor type
-Have fully recovered from previous chemo, immunotherapy or radiotherapy
What is Involved?
If you choose to join this study you will:
- Get the study drug XL 184 daily during each cycle
-- Each cycle lasts 28 days
- Get tests and imaging scans to monitor tumor changes
Participating Institutions:
  • Duke University Health System
View this trial at ClinicalTrials.gov

AALL1621 A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults w/Relapsed or Refract
Principal Investigator: Wagner, Lars
Protocol Number: PRO00087382

Age Group: Both
Scope: National

Phase: II (Cancer Control)
Disease Site: Myeloid and Monocytic Leukemia

Contact: Duke Recruitment Innovation Center
Phone: 919.681.5698

What is the Condition Being Studied?
Children and young adults with Relapsed or or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
What is the Purpose of this Study?
We are doing this study to find out what effect (good and/or bad) the study drug Inotuzumab Ozogamicin has on children and young adults with relapsed or refractory B-ALL. 
Who Can Participate in the Study?
Children and young adults who:
- Are ages 1-22 years of age
- Have currently or previously been diagnosed with B-Acute Lymphoblastic Leukemia (B-ALL)
- Have recovered from any previous systemic therapy 
What is Involved?
If you choose to join this study, you will:
-Get 2-6 cycles of Inotuzumab Ozagamicin, lasting 1 month per cycle
-Get Methotrexate on day one during cycle 1 and on day 28 of cycles 2, 4 and 6.
-Get about 3-5 mL of blood collected prior to treatment and at three time points during cycle 1 and 4 time points during cycle 2
Participating Institutions:
  • Duke University Health System
View this trial at ClinicalTrials.gov

APEC1621 Pediatric MATCH Study (Solid tumors, non-Hodgkin lymphomas, sarcoma, CNS tumors)
Principal Investigator: Kreissman, Susan
Protocol Number: PRO00087722

Age Group: Both
Scope: National

Phase: II (Cancer Control)
Disease Site: Bones and Joints; Soft Tissue

Contact: Duke Recruitment Innovation Center
Phone: 919.681.5698

What is the Condition Being Studied?
Solid tumors, non-Hodgkin lymphomas, sarcoma, CNS tumors
What is the Purpose of this Study?
We are doing this study to see if different study drugs or drug combinations that target specific genetic changes found in some cancers will shrink the tumor and/or prolong the time to progression. 
Who Can Participate in the Study?
Children and adults with recurrent solid tumors, lymphoma, and CNS tumors who:
- Are aged 12 months to less than 21 years of age 
- Have no uncontrolled infection
- Have had a prior solid organ transplant
What is Involved?
If you choose to join this study, you will:
- Have tumor tissue from a biopsy sent to a lab for genetic testing
-- If the tumor tissue has a genetic change that is targeted by one or more of the study drugs being tested in this study, you may be assigned to that study. 
Participating Institutions:
  • Duke University Health System
View this trial at ClinicalTrials.gov

AHEP1531: Hepatoblastoma in Children & Young Adults
Principal Investigator: Wagner, Lars
Protocol Number: PRO00101163

Age Group: Both
Scope:

Phase: II/III
Disease Site: Liver

Contact: Duke Recruitment Innovation Center
Phone: 919.681.5698

What is the Condition Being Studied?
Children and young adults with Hepatoblastoma 
What is the Purpose of this Study?
We are doing this study to compare the effects (good and/or bad) of cisplatin with the combination of chemotherapy in treating children and young adults with hepatoblastoma or liver cancer after surgery.
Who Can Participate in the Study?
Adults and children who:
- Are up to age 30
- Have a newly diagnosed primary pediatric hepatic malignancy
What is Involved?
If you choose to join this study, you will:
- Get treatments based on the group you are assigned 

-- Group A: patients with very low risk disease
-- Group B: patients with low risk disease
-- Group C: patients with intermediate risk disease
-- Group D: patients with high risk disease

Depending on your assigned group, you may:
-- Get chemotherapy drugs such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and/or oxaliplatin.
--- Be randomized (like flipping a coin) to different types or doses of chemotherapy
-- Have surgery to remove your tumor
View this trial at ClinicalTrials.gov